Trials In Focus: FDA Guidance Aims To Tackle Challenges In Multi-Endpoint Trials
Guidance Targets ‘Multiplicity Problem’
Beam Therapeutics also announced that it dosed the first patient in its Phase I/II sickle cell disease trial; Vyne stepped into the increasingly competitive vitiligo space, while Tracon moved further into sarcomas in its checkpoint inhibitor program, and Telix started a small trial of its drug in brain cancer.
You may also be interested in...
With Opzelura approved for vitiligo in July, Incyte acquires Villaris and its preclinical IL-15-targeted antibody to potentially add to its vitiligo portfolio.
The Australian company is steadily growing its photoprotective drug in adults with erythropoietic protoporphyria but also sees a big opportunity in the pigment loss disorder.
Beam is the latest allogeneic CAR-T developer to face a regulatory hold-up, but other candidates using its pioneering base-editing technology are now progressing.